Positive clinical results of Palobiofarma´s adenosine A1 antagonist PBF-680 presented at the European Respiratory Society meeting

por Palobiofarma

6 years ago

The results of an allergen POC trial in asthmatics will summarized by Dr. David Ramos, principal investigator of the PBF-680 clinical program, in an oral presentation titled:

Palobiofarma announces positive results from the Phase II clinical trial evaluating the preliminary efficacy and safety of its adenosine A1 receptor antagonist PBF-680 in mild to moderate asthmatics patients

por Palobiofarma

6 years ago
drug, asthmatics, clinical trial

The results confirm a clinically and statistically significant improvement in trough FEV1 of asthmatic patients taking 10mg of PBF-680 for 14 days compared to placebo.

Palobiofarma recibe el apoyo del CDTI para su proyecto de investigación contra el COVID-19

por Palobiofarma

6 years ago
CDTI, covid-19, investigación

Investigaciones recientes han identificado a la proteína convertidora de angiotensina 2 (de sus siglas en inglés angiotensin converting enzyme 2 - ACE2) como puerta de entrada a las células por el ...

XOMA and Inveready Acquires Royalty Interest Position in Six Clinical-Stage Assets from Palobiofarma

por Palobiofarma

7 years ago
Inveready, Novartis, tumor, inhibitor, adenosine

XOMA Corporation (NASDAQ: XOMA), announced today it has acquired a royalty interest in six clinical-stage assets targeting the adenosine pathway for $10.0 million from Palobiofarma S.L.One of the asse...

Palobiofarma receives milestone payment from Novartis

por Palobiofarma

10 years ago
Palobiofarma, cáncer de pulmón, Novartis, PBF-509, PDR001

The milestone payment is the first from the licensing agreement between the two companies. Under the terms of that agreement, which was signed in September 2015, Novartis has exclusive development and...

Palobiofarma firma un contrato de licencia con la farmacéutica suiza Novartis para su fármaco contra el Cáncer de Pulmón

por Palobiofarma

11 years ago
cáncer de pulmón, drug development, acuerdo de licencia, fármaco PBF-509, Novartis, Palobiofarma

Mediante la firma de este acuerdo de licencia, Palobiofarma cede al gigante farmacéutico suizo los derechos de su fármaco PBF-509, un producto descubierto y patentado por la empresa Navarra, que se...